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license (http://creativecommons.org/licenses/by-nc-nWe read with interest and comment on mechanism of effect
from the paper by Nakao and colleagues (1), entitled “Nalfuraﬁne
hydrochloride, a selective k opioid receptor agonist, has no rein-
forcing effect on intravenous self-administration in rhesus mon-
keys”, published in the Journal of Pharmacological Sciences. The
authors suggest that while nalfuraﬁne is a potent and selective
agonist at the k opioid receptor, it also possesses weak and partial
agonist activity at m opioid receptors. Given that opioids, especially
those acting at m receptors, carry a potential risk of abuse, Nakao
et al. evaluated the reinforcing effects of nalfuraﬁne by intrave-
nous self-administration of nalfuraﬁne in rhesus monkeys. The
investigation has demonstrated that nalfuraﬁne has no reinforcing
effect in rhesus monkeys in an intravenous self-administration
paradigm. Nakao et al. conclude that nalfuraﬁne can be used for
the treatment of intractable pruritus in hemodialysis or chronic
liver disease patients with minimal concern regarding the risk of
drug abuse (1).
However, a few decades ago, the agonism of the k opioid recep-
tor was shown to elicit dysphoric and psychotomimetic effects in
humans (2,3). In a paper by Pfeiffer et al., the psychotomimetic ef-
fects which subjects reported included racing thoughts, feelings of
body distortion, disturbances in the perception of space and time,
abnormal visual experiences, including moving lines or walls or co-
lor phenomena, and uncontrolled laughter. We question how, and
if, such psychotomimetic experiencewould bemanifested in rhesus
monkeys.
Further, Nakao et al. reason that animal studies of abuse liabil-
ity have the advantages of utilizing a wider range of doses and
including a positive control drug. Nalfuraﬁne does not induce
conditioned place preference in mice or rats, indicating that the
drug does not produce a rewarding effect (1). However, DiMattio
and colleagues (4) have recently demonstrated k opioid receptor
agonists display functional selectivity at both human k opioid re-
ceptor and mouse k opioid receptor in neuro-2a mouse neuroblas-
toma cells. They conclude that the novel ﬁnding in their study isacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).that there are species differences in functional selectivity of
several full agonists, which raises the possibility that results ob-
tained from one species with k opioid receptor agonists may not
be applicable to the other (4).
The behavioral actions of m and k agonists are not simply
different, but in most aspects quite opposite (5). m Agonists such
as morphine induce locomotor hyperactivity in most laboratory
species, while k agonists cause overall locomotor depression in
mice, rats, and monkeys (5). Contrary to the euphoriant action of
m opioids, k-agonists are aversive and dysphoric (5).
A recent review paper by Shigeki Inui (6) concludes that nalfur-
aﬁne is safe and effective for the treatment of hemodialysis pa-
tients with uremic pruritus resistant to antihistamines.
Interestingly, of all the adverse effects reported during a 52-
week long-term trial by patients, which included insomnia
(15.2%), constipation (3.3%), somnolence (1.9%), dizziness (0.9%),
pruritus (0.9%), diarrhea (0.9%), malaise (0.9%), mood alteration
(0.9%), etc., there was no reported incidence of psychotomimetic
or dysphoric effects (6).
In reviewing this paper and the literature, it appears likely that
the results of the present investigation represent biased agonism,
referring speciﬁcally to the ability of a ligand to activate a subset
of a receptor's signaling cascade (7). This concept has recently
been reviewed at the kappa opioid receptor by Dogra and Yadav
(8) and may help to better explain the unexpected result that
none of the 211 patients reported any psychotomimetic and
dysphoric effects, realizing that k agonism in humans is known to
elicit these types of adverse effects.External funding
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